CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market filing for the Category 1 drug prusogliptin, intended for the treatment of type 2 diabetes, has been accepted for review by the National Medical Products Administration (NMPA).
Clinical Study Results and Efficacy of Prusogliptin
A clinical study has demonstrated that prusogliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, exhibits a sustained hypoglycemic effect and is associated with a low incidence of adverse reactions. This places prusogliptin as a promising treatment option in the management of type 2 diabetes.
Market Potential of DPP-4 Inhibitors in China
The market for DPP-4 inhibitors in China, excluding compound formulations, was valued at RMB 4 billion (578.5 million USD) in 2021, marking an increase of nearly 25% year-on-year. This growth underscores the significant demand and potential for new treatments in the diabetes management space within the country.-Fineline Info & Tech
